Oecd Health Policy Studies Pharmaceutical Innovation And Access To Medicines
Oecd Health Policy Studies Pharmaceutical Innovation And Access To Medicines Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Oecd Health Policy Studies Pharmaceutical Innovation And Access To Medicines book. This book definitely worth reading, it is an incredibly well-written.
OECD Health Policy Studies Pharmaceutical Innovation and Access to Medicines by OECD Pdf
This report reviews the important role of medicines in health sytems, describes recent trends in pharmaceutical expenditure and financing, and summarises the approaches used by OECD countries to determine coverage and pricing.
Pharmaceutical Innovation and Access to Medicines by OECD Pdf
This report reviews the important role of medicines in health sytems, describes recent trends in pharmaceutical expenditure and financing, and summarises the approaches used by OECD countries to determine coverage and pricing.
OECD Health Policy Studies Pharmaceutical Pricing Policies in a Global Market by OECD Pdf
This report assesses how pharmaceutical pricing and reimbursement policies have contributed to the achievement of certain health policy objectives, and it examines the national and transnational effects of these policies.
OECD Health Policy Studies Pharmaceutical Pricing Policies in a Global Market by OECD Pdf
This report assesses how pharmaceutical pricing and reimbursement policies have contributed to the achievement of certain health policy objectives, and it examines the national and transnational effects of these policies.
New Health Technologies Managing Access, Value and Sustainability by OECD Pdf
This report discusses the need for an integrated and cyclical approach to managing health technology in order to mitigate clinical and financial risks, and ensure acceptable value for money.
Pharmacogenetics: Opportunities and Challenges for Health Innovation by OECD Pdf
This book reviews how the emergence of pharmacogenetics will impact the efficiency of pharmaceutical R&D and improve healthcare decision making and clinical care. It discusses what policies need to change in order for the public to reap the benefits from advances in diagnostic genetic testing.
Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade by World Intellectual Property Organization Pdf
This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies.
OECD Health Policy Studies Achieving Better Value for Money in Health Care by OECD Pdf
This report report examines selected policies that may help countries better achieve the goal of improved health system efficiency and thus better value for money.
WHO guideline on country pharmaceutical pricing policies by Anonim Pdf
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
OECD Health Policy Studies Health Data Governance Privacy, Monitoring and Research by OECD Pdf
This report identifies eight key data governance mechanisms to maximise benefits to patients and to societies from the collection, linkage and analysis of health data, and to minimise risks to both patient privacy and the security of health data.
Equitable Access to High-Cost Pharmaceuticals by Zaheer-Ud-Din Babar Pdf
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines. Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs Incorporates existing guidelines and recommendations by international organizations Compares and contrasts how different countries fund and police high-cost drug access Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing Reviews novel pharmaceuticals of current research interest
Price Setting and Price Regulation in Health Care by OECD,World Health Organization,Barber Sarah L,Lorenzoni Luca,Ong Paul Pdf
The objectives of this study are to describe experiences in price setting and how pricing has been used to attain better coverage, quality, financial protection, and health outcomes. It builds on newly commissioned case studies and lessons learned in calculating prices, negotiating with providers, and monitoring changes. Recognising that no single model is applicable to all settings, the study aimed to generate best practices and identify areas for future research, particularly in low- and middle-income settings. The report and the case studies were jointly developed by the OECD and the WHO Centre for Health Development in Kobe (Japan).
This report explores how data and digital technology can help achieve policy objectives and drive positive transformation in the health sector while managing new risks such as privacy, equity and implementation costs. It examines the following topics: improving service delivery models; empowering people to take an active role in their health and their care; improving public health; managing biomedical technologies; enabling better collaboration across borders; and improving health system governance and stewardship. It also examines how health workforces should be equipped to make the most of digital technology. The report contains findings from surveys of OECD countries and shares a range of examples that illustrate the potential benefits as well as challenges of the digital transformation in the health sector. Findings and recommendations are relevant for policymakers, health care providers, payers, industry as well as patients, citizens and civil society.
OECD Health Policy Studies Value for Money in Health Spending by OECD Pdf
This publication examines current efforts to improve health care efficiency, including tools that show promise in helping health systems provide the best care for their money.
OECD Science, Technology and Innovation Outlook 2021 Times of Crisis and Opportunity by OECD Pdf
In immediate responses to the COVID-19 crisis, science and innovation are playing essential roles in providing a better scientific understanding of the virus, as well as in the development of vaccines, treatments and diagnostics. Both the public and private sectors have poured billions of dollars into these efforts, accompanied by unprecedented levels of global cooperation.
